Summit Wealth & Retirement Planning’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.16M Buy
1,260
+238
+23% +$241K 0.28% 39
2025
Q4
$1.1M Sell
1,022
-21
-2% -$20.1K 0.26% 36
2025
Q3
$796K Buy
1,043
+39
+4% +$29K 0.2% 40
2025
Q2
$783K Buy
1,004
+406
+68% +$315K 0.21% 37
2025
Q1
$494K Buy
598
+52
+10% +$43.3K 0.15% 44
2024
Q4
$422K Buy
546
+250
+84% +$207K 0.13% 51
2024
Q3
$262K Buy
+296
New +$266K 0.08% 57
2022
Q4
Sell
-1,666
Closed -$539K 117
2022
Q3
$539K Hold
1,666
0.21% 59
2022
Q2
$540K Buy
+1,666
New +$500K 0.21% 62
2019
Q3
Sell
-2,271
Closed -$252K 127
2019
Q2
$252K Hold
2,271
0.15% 116
2019
Q1
$295K Sell
2,271
-11
-0.5% -$1.34K 0.18% 111
2018
Q4
$264K Buy
+2,282
New +$255K 0.2% 98

Other funds holding LLY

Summit Wealth & Retirement Planning's LLY Position: Q1 2026 in Review

Summit Wealth & Retirement Planning increased its Eli Lilly (LLY) stake by 23% in Q1 2026, buying an estimated $241K and bringing the position to 1,260 shares worth $1.16M. The position accounts for 0.28% of the portfolio, ranked #39.

Summit Wealth & Retirement Planning first reported a position in LLY in Q4 2018 and has held it in 12 quarters since. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Summit Wealth & Retirement Planning held 1,260 shares of Eli Lilly worth $1.16M as of Q1 2026.
  • Summit Wealth & Retirement Planning bought 238 Eli Lilly shares in Q1 2026, an estimated $241K.
  • Eli Lilly made up 0.28% of Summit Wealth & Retirement Planning's portfolio in Q1 2026, its #39 holding.
  • Summit Wealth & Retirement Planning first reported a position in Eli Lilly in Q4 2018 and has held it in 12 quarters since.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Summit Wealth & Retirement Planning's 13F filing for Q1 2026, filed 11 May 2026.